Similarly, higher ARPC1A expression in DSS analysis predicted poorer prognosis in LGG, LIHC, GBM, LUAD, UVM, and ACC patients and protected against PCPG (Figure 4C). This evidence concerns the gene ARPC1A and glioblastoma.